Autobahn Therapeutics

SAN DIEGO, CA · Biotech · Private

CNS regenerative therapeutics leveraging endogenous biological repair mechanisms

Claim this profile

Follows are private to you and power your alerts

Updated · autobahntx.com

Sector
Biotech
Headquarters
SAN DIEGO, CA
Latest Form D
$101M, Aug 2024
Total capital
$101M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$101M
1 Form D · last Aug 2024
27 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
7
33 pending · first 2023
Rank in peer group#213 of 1449

Capital timeline

2024FEDERAL ↑EQUITY ↓Cumulative $101M1st Form D$101M
2024FEDERAL ↑EQUITY ↓Cumulative $101M1st Form D$101M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$101M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#213 · top 15%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Benjamin CravattDirectorNamed in SEC Form D filings
  • Bonnie J van WilgenburgDirectorNamed in SEC Form D filings
  • John BorkholderExecutive OfficerNamed in SEC Form D filings
  • Kevin FinneyExecutive Officer, DirectorNamed in SEC Form D filings
  • Kristina BurowDirectorNamed in SEC Form D filings
  • Philip J DeSouzaDirectorNamed in SEC Form D filings
Show all 10 people
  • Scott GiacobelloDirectorNamed in SEC Form D filings
  • Thomas CahillDirectorNamed in SEC Form D filings
  • Timothy AndersonDirectorNamed in SEC Form D filings
  • Uwe J SchoenbeckDirectorNamed in SEC Form D filings

What it has protected

USPTO · 7 granted of 40
Show all 40 patent records
  • Isotopic Thyromimetic CompoundsSep 22, 2026 · US 12,741,932Granted
  • Fatty Acid Amide Hydrolase (faah) Cleavable Prodrugs Of Thyromimetics And Combination With Peripherally Restricted Faah InhibitorsMay 26, 2026 · US 12,637,413Granted
  • ThyromimeticsMar 31, 2026 · US 12,590,072Granted
  • ThyromimeticsJan 20, 2026 · US 12,528,761Granted
  • Novel ThyromimeticsNov 11, 2025 · US 12,466,781Granted
  • Methods For The Treatment Of DepressionOct 2, 2025 · Application 19109521Pending
  • Fatty Acid Amide Hydrolase (faah) Cleavable Prodrugs Of Brain Targeting Actives And Combination With Peripherally Restricted Faah InhibitorsAug 8, 2024 · Application 18558709Pending
  • Novel ThyromimeticsNov 28, 2023 · US 11,827,596Granted
  • Isotopic Thyromimetic CompoundsNov 2, 2023 · Application 18000508Pending
  • ThyromimeticsAug 3, 2023 · Application 18002036Pending
  • Novel ThyromimeticsJun 6, 2023 · US 11,667,606Granted
  • Methods For The Treatment Of DepressionApplication 63375192Pending
  • Amide Prodrugs And Uses ThereofApplication 63370753Pending
  • Amide Prodrugs And Uses ThereofApplication 63367569Pending
  • Pharmaceutical CompositionsApplication PCTUS2022028164Pending
  • Pharmaceutical CompositionsApplication PCTUS2022028187Pending
  • Pharmaceutical CompositionsApplication 63274856Pending
  • ThyromimeticsApplication PCTUS2021037862Pending
  • Amide Prodrugs And Uses ThereofApplication 19101875Pending
  • ThyromimeticsApplication PCTUS2021037833Pending
  • ThyromimeticsApplication PCTUS2021037788Pending
  • Isotopic Thyromimetic CompoundsApplication PCTUS2021035679Pending
  • Pharmaceutical CompositionsApplication 63185254Pending
  • Pharmaceutical CompositionsApplication 63185253Pending
  • Novel ThyromimeticsApplication PCTUS2020062229Pending
  • ThyromimeticsApplication 63040452Pending
  • Novel ThyromimeticsApplication 63040448Pending
  • Novel ThyromimeticsApplication 63040446Pending
  • Novel ThyromimeticsApplication 63040453Pending
  • Isotopic Thyromimetic CompoundsApplication 63034328Pending
  • Novel ThyromimeticsApplication PCTUS2020020199Pending
  • Novel ThyromimeticsApplication 62953100Pending
  • Novel ThyromimeticsApplication 62907455Pending
  • Novel ThyromimeticsApplication 62812890Pending
  • Amide Prodrugs And Uses ThereofApplication 19581994Pending
  • Amide Prodrugs And Uses ThereofApplication 19581993Pending
  • Amide Prodrugs And Uses ThereofApplication 19514133Pending
  • Amide Prodrugs And Uses ThereofApplication 18880174Pending
  • Amide Prodrugs And Uses ThereofApplication PCTUS2024052849Pending
  • Amide Prodrugs And Uses ThereofApplication PCTUS2024052851Pending
  • Adicet BioSimilar federal contract value in Biotech · null in contracts
  • REGENXBIO Inc.Similar federal contract value in Biotech · null in contracts
  • RallybioSimilar federal contract value in Biotech · null in contracts
  • Amicus TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • ReCode TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • NuPeak Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .